Patents by Inventor Zoltán Szilvássy

Zoltán Szilvássy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150366852
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: June 23, 2015
    Publication date: December 24, 2015
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Michael Brownstein, Kálmán Takács, Laszlo Vigh, József Mandl, Balázs Sümegi, Sandor Bernath, Attila Kolonics, Gábor Balogh, Janos Egri
  • Publication number: 20140170233
    Abstract: The invention relates to a natural feed mixture for breeding domesticated water birds, comprising a high carbohydrate containing basic component poor in methyl-donors, a component rich in carbohydrates, having hepatic insulin-sensitizing properties, hypothalamic appetite-stimulating plant parts, natural substances blocking cholesterol synthesis in the liver, and an additive for protecting the formation of non-cholesterol- mevalonate products.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: LIBAFOOD TECH Kft.
    Inventors: Zoltán SZILVÁSSY, Péter TÓTH, Enikö FÖLDI, Zsolt Tibor LAMPÉ, József MÉSZÁROS, Pál ANTON
  • Publication number: 20120129769
    Abstract: The subject of the invention is an orally administerable pharmaceutical preparation containing a combination of biotechnologically produced human recombinant insulin and/or modified insulin or an analogue and/or derivative thereof, a protease inhibitor and a high molecular weight (natural) protein. The invention relates to a method for the production of the pharmaceutical preparation as well. The subject of the invention also covers the use of the pharmaceutical preparation and a method for the treatment of diabetes in mammals.
    Type: Application
    Filed: August 2, 2010
    Publication date: May 24, 2012
    Inventors: Zoltán Szilvássy, Barna Peitl, József Németh
  • Patent number: 8048873
    Abstract: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: November 1, 2011
    Assignee: N-Gene Research Laboratories, Inc.
    Inventors: Zoltán Szilvássy, György Rabloczky, András Rabloczky, legal representative, Péter Literáti Nagy
  • Publication number: 20100311719
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: August 17, 2010
    Publication date: December 9, 2010
    Inventors: Péter Literáti Nagy, Jesse Roth, Zoltán Szilvássy, Kálmán Tory, Mike Brownstein, Kálmán Takács, László Vígh, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
  • Patent number: 7767694
    Abstract: The present invention is directed to a method of treating gastrointestinal motility disorders in a subject in need thereof which includes: administering a therapeutically effective amount of O-(3-piperidino-2-hydroxypropyl) nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof, wherein the gastrointestinal motility disorders include reflux esophagitis, type II biliary and pancreatic sphincter of Oddi dysfunction, type III biliary and pancreatic sphincter of Oddi dysfunction, postcholecystectomy syndrome, non-ulcerative colitis or fecal incontinences.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 3, 2010
    Assignee: N-Gene Research Laboratories Inc.
    Inventors: Zoltan Szilvassy, Altila Kolonics, Kálmán Tory, Peter Literatinagy
  • Patent number: 7763601
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime (BGP-15) or a pharmaceutically suitable acid addition salt thereof can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight gain.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: July 27, 2010
    Assignee: N-Gene Research Laboratories, Inc.
    Inventors: Péter Literáti Nagy, Zoltán Szilvássy, Kálmán Tory, László Vígh, Kálmán Takács, József Mandl, Balázs Sümegi, Sándor Bernáth, Attila Kolonics, Gábor Balogh, János Egri
  • Publication number: 20100048627
    Abstract: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.
    Type: Application
    Filed: November 6, 2009
    Publication date: February 25, 2010
    Inventors: Zoltan SZILVASSY, György RABLOCZKY, Péter LITERÁTI NAGY, András RABLOCZKY
  • Patent number: 7635674
    Abstract: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: December 22, 2009
    Assignee: N-Gene Research Laboratories, Inc.
    Inventors: Zoltán Szilvássy, György Rabloczky, András Rabloczky, legal representative, Péter Literáti Nagy
  • Publication number: 20090281143
    Abstract: O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.
    Type: Application
    Filed: December 10, 2008
    Publication date: November 12, 2009
    Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Attila Kolonics, Sandor Bernath, Laszlo Vigh, Jesse Roth, G. Alexander Fleming, Michael Brownstein, Janos Egri
  • Publication number: 20090149498
    Abstract: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition that restores and/or enhances the activity of the neuronal nitric oxide synthase enzyme.
    Type: Application
    Filed: February 5, 2009
    Publication date: June 11, 2009
    Inventors: Zoltan Szilvassy, Attila Kolonics, Kalman Tory, Peter Literatinagy
  • Publication number: 20090054487
    Abstract: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition increasing the mitochondrial genesis.
    Type: Application
    Filed: June 13, 2005
    Publication date: February 26, 2009
    Inventors: Attila Kolonics, Kalman Tory, Peter Literati Nagy, Zoltan Szilvassy, Lajos Laszlo
  • Publication number: 20080108602
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 8, 2008
    Inventors: Peter Literati Nagy, Jesse Roth, Zoltan Szilvassy, Kalman Tory, Mike Brownstein, Kalman Takacs, Laszlo Vigh, Jozsef Mandi, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
  • Publication number: 20080108673
    Abstract: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 8, 2008
    Inventors: Peter Literati Nagy, Zoltan Szilvassy, Kalman Tory, Laszlo Vigh, Kalman Takacs, Jozsef Mandl, Balazs Sumegi, Sandor Bernath, Attila Kolonics, Gabor Balogh, Janos Egri
  • Publication number: 20070281972
    Abstract: The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition that restores and/or enhances the activity of the neuronal nitric oxide synthase enzyme.
    Type: Application
    Filed: June 13, 2005
    Publication date: December 6, 2007
    Applicant: N-GENE RESEARCH LABORATORIES INC.
    Inventors: Zoltan Szilvassy, Attila Kolonics, Kalman Tory, Peter Literatinagy
  • Publication number: 20040068005
    Abstract: Pharmaceutical combinations for treatment and/or prevention of all sorts, periods and complications of diabetes mellitus in mammals, thus including the pre-diabetic diseases and their complications, optionally including furthermore ischaemic heart disease comprising an effective dose of at least one enzymatic nitric oxide (NO) donor active ingredient and optionally comprising an effective dose of at least one antidiabetic active ingredient, and further optionally comprising usual pharmaceutically acceptable carriers and/or other auxiliaries. The combination may consist of more than one pharmaceutical compositions. The effective doses related to the new insulin-sensitizing effect are considerably lower than the usual doses related to the know effect of most active substances dues to metabolic effects that influence insulin sensitivity in healthy and insulin resistant mammals. The usual dose of NO-donors is necessary when the patient has also ischaemic heart disease.
    Type: Application
    Filed: October 17, 2003
    Publication date: April 8, 2004
    Inventors: Zoltan Szilvassy, Arpad Tosaki, Jozsef Nemeth, Peter Kovacs, Csaba Pankucsi, Ferenc Hernadi, Peter Ferdinandy